Form 4: Acurx Pharmaceuticals Director James J. Donohue Acquires Stock Options

Director James J. Donohue acquired 12,000 stock options in Acurx Pharmaceuticals on June 17, 2024, related to his board service.

Summary

• James J. Donohue, a director of Acurx Pharmaceuticals, acquired 12,000 stock options on June 17, 2024.
• The options have an exercise price of $2.38.
• These options were granted as part of the Issuer's Director Compensation Policy.
• The options vest on June 17, 2025.
• Following the transaction, Donohue directly owns 12,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is neither particularly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to director compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation of company directors.

Comparison to Industry Standards

• Director compensation packages often include stock options to align the interests of directors with those of shareholders.
• The vesting schedule of one year is fairly standard for director stock options.
• The specific number of options granted and the exercise price would be benchmarked against similar companies in the pharmaceutical industry to assess competitiveness.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates